---
document_datetime: 2023-09-21 18:26:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_en.pdf
document_name: vaniqa-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8255402
conversion_datetime: 2025-12-28 17:46:02.807663
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU-Numbers      | Invented name   | Strength   | Pharmaceutical Form   | Route of administration   | Packaging   | Content (concentration)   | Package sizes   |
|-----------------|-----------------|------------|-----------------------|---------------------------|-------------|---------------------------|-----------------|
| EU/1/01/173/001 | Vaniqa          | 11.5%      | Cream                 | Cutaneous use             | Tube (HDPE) | 15 g (11.5% w/w)          | 1 tube          |
| EU/1/01/173/002 | Vaniqa          | 11.5%      | Cream                 | Cutaneous use             | Tube (HDPE) | 30 g (11.5% w/w)          | 1 tube          |
| EU/1/01/173/003 | Vaniqa          | 11.5%      | Cream                 | Cutaneous use             | Tube (HDPE) | 60 g (11.5% w/w)          | 1 tube          |